Anti-inflammatory Therapeutics Market to Witness a Pronounce Growth During 2019 – Top Key players like  Pfizer, Inc., AbbVie, Inc., Johnson & Johnson, GlaxoSmithKline plc, Merck, Novartis AG, F. Hoffmann-La Roche, Eli Lily and Company, AstraZeneca

The Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR of 8.6% over the forecast period, owing to the rising healthcare expenditure, disposable income of individuals, increasing popularity of biologics and better healthcare access. Increase in the number of autoimmune and respiratory diseases, new drugs in development pipeline and increased usage of OTC NSAIDs are the major factors driving the Asia-Pacific anti-inflammatory market. Moreover, increasing awareness of anti-inflammatory biologics and favorable government initiatives in the Asia-Pacific region are expected to drive the market during the analysis period. Factors, such as side effects of anti-inflammatory drugs and uncertain patent legislations, i.e., compulsory licensing in India would continue to impede the market growth.

The industry is segmented on the basis of indication, drug class and geography. The indications considered in this report include arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease and other inflammatory diseases. Among indications, arthritis was the dominant segment accounting for 41.3% of the APAC anti-inflammatory therapeutics market in 2014 and holds potential for growth during the forecast period. Anti-inflammatory biologics are the most preferred drugs for treatment of arthritis.

Request a sample copy at

Key players profiled in the report include  Pfizer, Inc., AbbVie, Inc., Johnson & Johnson, GlaxoSmithKline plc, Merck & CO., Inc., Novartis AG, F. Hoffmann-La Roche AG, Eli Lily and Company, AstraZeneca PLC and Amgen.

On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Anti-inflammatory biologics holds the largest share among drug classes accounting for around 50% share of the market, and is expected to grow rapidly during the forecast period.

Geographically, the market is segmented into six countries namely Japan, China, India, Australia, South Korea, Indonesia and others. Among these countries, Japan holds the largest share in the industry; however, China is expected to exhibit the fastest growth during the forecast period. Major market players have adopted strategies such as collaborations, indication expansions and product launches to expand their market presence. In 2014, Novartis got marketing approval for the drug Cosentyx (secukinumab) in Japan for the treatment of psoriatic arthritis. The company has filed new patents to overcome the issues of patent expiries of their existing drugs and to gain a prominent market share.

Ask for Discount at

Table of Content








7.1 Pfizer Inc.
7.2 AbbVie Inc.
7.3 Johnson & Johnson
7.4 GlaxoSmithKline plc
7.5 Merck & Co., Inc.
7.6 Novartis AG
7.7 F. Hoffmann-La Roche AG
7.8 Eli Lily and Company
7.9 AstraZeneca PLC.
7.10 Amgen Inc.

Get Complete Report at

Contact Us:
Call: +1-646-491-9876
Email: [email protected]

About ReportsWeb: is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Posted by on Tuesday October 08 2019, 7:45 AM EST. All trademarks acknowledged. Filed under Business Services, Featured Press Release, Technology, Media, & Telecommunications. Comments and Trackbacks closed. Follow responses: RSS 2.0

Comments are closed

News Categories

Featured Press Releases

Log in